MLAB · Mesa Laboratories Inc /Co/ · Financials
One customer — 20% of revenue (fiscal 2026)
“In our Clinical Genomics division, a significant portion of revenues is generated from ongoing purchases by a relatively small number of established customers, with a single customer accounting for approximately 20% of the division's revenues in fiscal 2026.”
Income-statement, balance-sheet and cash-flow figures from SEC filings, plus a debt profile anchored in the latest 10-K and updated by each 10-Q and debt exhibit.
Chart any reported metric, KPI or segment over time — the full statement history lives here
| Line Item | TTM | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 | FY2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $249.73M | $249.13M | $240.98M | $216.19M | $219.08M | $184.34M | $133.94M | $117.69M | $103.14M | $96.18M | $93.67M | $84.66M | $71.33M | $52.72M | $46.44M | $39.62M | $34.23M | |
| $89.38M | $90.86M | $90.11M | $82.94M | $85.39M | $75.25M | $46.92M | $52.33M | $42.22M | $41.56M | $40.43M | $33.25M | $27.94M | $21.04M | $17.57M | $16.11M | $14.66M | |
| $160.34M | $158.27M | $150.87M | $133.25M | $133.69M | $109.09M | $87.01M | $65.36M | $60.92M | $54.62M | $53.24M | $51.41M | $43.39M | $31.69M | $28.86M | $23.51M | $19.57M | |
| — | 63.53% | 62.61% | 61.64% | 61.02% | 59.18% | 64.97% | 55.54% | 59.06% | 56.79% | 56.84% | 60.73% | 60.83% | 60.1% | 62.16% | 59.35% | 57.17% | |
| $20.05M | $20.31M | $19.52M | $19.3M | $20.49M | $15.77M | $10.39M | $6.36M | $3.51M | $3.54M | $4.16M | $3.97M | $3.29M | $2.32M | $2.01M | $1.36M | $1.44M | |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | $3.91M | $3.69M | |
| $78.08M | $78.66M | $73.33M | $72.87M | $72.44M | $60.31M | $45.79M | $38.17M | $31.3M | $26.26M | $22.81M | $23.62M | $17.06M | $11.46M | $9.12M | $5.42M | $4.58M | |
| $17.86M | $18.02M | $19.15M | $27.34M | $28.82M | $21.81M | $14.51M | $10.64M | $7.09M | $6.93M | $6.45M | $5.79M | $4.68M | $2.98M | $2.6M | $1.49M | $1.18M | |
| $33.87M | — | — | — | $33.82M | $25.07M | $17.66M | $12.99M | $9.43M | $9.47M | $8.74M | $7.17M | $5.66M | $3.84M | $3.43M | $2.22M | $1.84M | |
| $137.87M | $139.76M | $134.53M | $405.33M | $130.37M | $104.39M | $74.66M | $57.44M | $51.14M | $52.44M | $36.93M | $35.09M | $27.53M | $19.9M | $15.76M | $11.03M | $9.7M | |
| $22.48M | $18.51M | $16.34M | -$272.08M | $3.32M | $4.7M | $12.36M | $7.92M | $9.78M | $2.18M | $16.31M | $16.32M | $15.86M | $11.79M | $13.1M | $12.48M | $9.86M | |
| — | 7.43% | 6.78% | -125.85% | 1.52% | 2.55% | 9.23% | 6.73% | 9.48% | 2.27% | 17.42% | 19.28% | 22.24% | 22.35% | 28.22% | 31.49% | 28.82% | |
| $37.06M | — | — | — | $37.14M | $29.77M | $30.02M | $20.91M | $19.21M | $11.65M | $25.05M | $23.5M | $21.52M | $15.63M | $16.54M | $14.69M | $11.71M | |
| $10.86M | $10.69M | $11.86M | $5.7M | $4.77M | $3.89M | $8.02M | $5.5M | $1.75M | $1.85M | — | — | — | — | — | — | — | |
| — | — | — | — | — | — | $107K | $960K | $29K | $5000 | — | — | — | — | — | — | — | |
| -$13.12M | -$6.5M | -$10.38M | -$3.57M | -$3.71M | -$1.13M | -$10.06M | -$4.06M | -$1.16M | -$1.88M | -$2.02M | -$768K | -$517K | $1.32M | -$126K | -$146K | -$113K | |
| $9.36M | $12.01M | $5.96M | -$275.65M | -$389K | $3.57M | $2.3M | $3.86M | $8.62M | $301K | $14.3M | $15.56M | $15.35M | $13.1M | $12.98M | $12.33M | $9.75M | |
| $4.56M | $5.3M | $7.94M | -$21.4M | -$1.32M | $1.7M | -$971K | $2.08M | $1.14M | $3.26M | $3.11M | $4.39M | $5.76M | $4.1M | $4.53M | $4.41M | $3.57M | |
| $4.8M | $6.71M | -$1.97M | -$254.25M | $930K | $1.87M | $3.27M | — | — | — | — | — | — | — | — | — | — | |
| — | 2.69% | -0.82% | -117.6% | 0.42% | 1.01% | 2.44% | — | — | — | — | — | — | — | — | — | — | |
| $4.8M | $6.71M | -$1.97M | -$254.25M | $930K | $1.87M | $3.27M | $1.78M | $7.48M | -$2.96M | $11.18M | $11.17M | $9.58M | $9M | $8.45M | $7.92M | $6.18M | |
| $4.41M | $13.13M | $3.01M | -$256.21M | -$15.53M | -$10.58M | $29.76M | -$6.59M | $5.11M | -$638K | $10.57M | $10.25M | $9.35M | $9M | $8.45M | — | — | |
| USD/shares | $0.85 | $1.22 | -$0.36 | -$47.20 | $0.17 | $0.36 | $0.66 | $0.42 | $1.95 | -$0.79 | $3.04 | $3.10 | $2.72 | $2.61 | $2.52 | $2.41 | $1.91 |
| USD/shares | $0.85 | $1.21 | -$0.36 | -$47.20 | $0.17 | $0.35 | $0.64 | $0.41 | $1.86 | -$0.79 | $2.91 | $2.97 | $2.63 | $2.49 | $2.35 | $2.29 | $1.86 |
| shares | — | 5.51M | 5.42M | 5.39M | 5.32M | 5.21M | 4.98M | 4.2M | 3.84M | 3.77M | 3.68M | 3.61M | 3.52M | 3.45M | 3.36M | 3.29M | 3.23M |
| shares | — | 5.57M | 5.42M | 5.39M | 5.36M | 5.34M | 5.12M | 4.37M | 4.03M | 3.77M | 3.84M | 3.76M | 3.65M | 3.61M | 3.59M | 3.46M | 3.33M |
Capital Returned to Shareholders
Cash spent on share repurchases and dividends per fiscal year, as reported on the cash-flow statement. Across FY2011–FY2026: $826K in buybacks, $41.72M in dividends.
Debt Profile
Annual debt figures are established from 10-K filings and updated by subsequent 10-Q and 8-K disclosures. Instrument balances are not summed into a company total unless the filing itself reports that total.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
Peer medians compare against the 13 similar-size Scientific & Technical Instruments companies (of 39 listed).
Valuation over time computed as of each quarter's filing date
Revenue Breakdown
Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.
Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.
By Segment (USD)
| Component | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|---|
| Sterilization and Disinfection Control | $101,567,000 | $93,418,000 | $75,124,000 | $64,609,000 | $59,044,000 | $53,119,000 | $49,660,000 | $46,297,000 |
| Calibration Solutions | $53,551,000 | $51,749,000 | $47,763,000 | $44,807,000 | $46,872,000 | $46,926,000 | $51,713,000 | — |
| Biopharmaceutical Development | $48,626,000 | $48,730,000 | $40,712,000 | $47,365,000 | $45,579,000 | $33,892,000 | $13,851,000 | $0 |
| Clinical Genomics | $45,386,000 | $47,081,000 | $52,588,000 | $62,299,000 | $32,840,000 | $0 | $0 | — |
| Cold Chain Monitoring | — | — | — | — | — | — | $13,729,000 | $13,806,000 |
| Continuous Monitoring | — | — | — | — | — | — | $13,729,000 | $13,806,000 |
| Instruments | — | — | — | — | — | — | $37,984,000 | $36,125,000 |
By Geography (USD)
| Component | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|---|
| United States | $116,895,000 | $116,615,000 | $106,395,000 | $117,281,000 | $99,068,000 | $71,387,000 | $66,344,000 | $64,828,000 |
| Other | $111,786,000 | $99,051,000 | $84,859,000 | $76,002,000 | $68,749,000 | $55,938,000 | — | — |
| China | $20,449,000 | $25,312,000 | $24,933,000 | $25,797,000 | $16,518,000 | $6,612,000 | — | — |
| Non Us | — | — | — | — | — | — | $51,343,000 | $38,307,000 |
By Product & Service (USD)
| Component | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|---|
| Product | $203,392,000 | $198,395,000 | $176,796,000 | $180,520,000 | $149,422,000 | $107,028,000 | $93,401,000 | $81,798,000 |
| Service | $45,738,000 | $42,583,000 | $39,391,000 | $38,560,000 | $34,913,000 | $26,909,000 | $24,286,000 | $21,337,000 |